COLL (72) AVBP (35) ARDX (35) ANNX (40) ⌘ Pro Terminal →

Helus Pharma Inc. (HELP) — RQD Stock Rating Cockpit

$10.71 -1.83% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Helus Pharma Inc. (HELP) carries a Roarable Rating of D (Sell) with 49/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $782.5M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for HELP)Realized 20D OHLCV Swing Band: ±12.5%

RSI-14 MOMENTUMNEUTRAL RANGE

44.730 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREHIGH QUALITY (7–9)

7 / 99-Pt Accounting

52-WEEK LASER RANGE61% OF RANGE

L: $4$10.71H: $15

1. Money & Cash Health● MIXED

Are profits real cash in the bank?

Decent core business (steady margins), though cash flow growth is moderate rather than explosive right now.

Factor Grade: C-RQD 12 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: D-RQD 14 / 40

3. Hidden Risks & Market Weather● WATCH

SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: D+RQD 23 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

JEV AI Jury Split (Battleground) on HELP

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

NEUTRAL (60)

14.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

NEUTRAL (65)

Altman-Z 4.20 and Piotroski 7/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (40)

14/40 institutional & smart-money positioning score with 10/20 macro alignment.

Bull Case: Why Buyers Like HELP

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Sensitive to high interest rates and tighter Federal Reserve market liquidity.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring HELP)

✓Walkthrough of HELP's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

HELP // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +101.69%📐 HORIZONTAL RANGE

2026-10-30O $10.53H $10.98L $10.42C $10.71VOL 1.15M

RES: $19.65SUP: $9.59SMA50: $11.96SMA200: $7.71

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

HELP Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 HELP Butterfly Map → + Track HELP →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on HELP today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for HELP. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for HELP today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (HELP)

Health Care Rank #359 of 1016 ⚔️ COLL vs HELP Full Matrix →

1. Head-to-Head Health Care Peer Comparison (HELP vs. COLL, AVBP, ARDX, ANNX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Helus Pharma Inc. (HELP) ranks #359 by composite RQD confidence (49/100, grade D) and #388 by equity capitalization ($782.5M). Within this direct 5-issuer industry benchmark cohort, COLL leads on earnings valuation at 12.4x trailing P/E, while COLL leads on capital efficiency and profitability with 85.0% ROIC and 59.3% gross margin. COLL currently holds the highest overall quantitative score in the immediate peer group at 72/100 (B) compared with HELP at 49/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
HELP ACTIVE Helus Pharma Inc.	D	49/100	—	—	—	-1.83%	$782.5M	Benchmark Subject
COLL Collegium Pharmaceutical Inc.	B	72/100	12.4x	59.3%	85.0%	+3.44%	$782.3M	/coll-vs-help →
AVBP ArriVent BioPharma Inc.	D-	35/100	—	—	-35.0%	+1.40%	$786.5M	/avbp-vs-help →
ARDX Ardelyx Inc.	D-	35/100	—	90.3%	-32.7%	0.00%	$772.5M	/ardx-vs-help →
ANNX Annexon Inc.	D-	40/100	—	—	-35.0%	-0.74%	$760.2M	/annx-vs-help →

2. HELP Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Helus Pharma Inc. (HELP) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $782.5M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. HELP Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is HELP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Helus Pharma Inc. (NASDAQ: HELP) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 49/100 at a spot price of $10.71 (-1.83% 1D, market cap $782.5M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, HELP ranks #359 in composite RQD confidence.

How does HELP compare to COLL and AVBP in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), HELP carries a Roarable D (49/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, COLL (Collegium Pharmaceutical Inc.) holds a B grade (72/100 RQD, P/E 12.4x, ROIC 85.0%, cap $782.3M) and AVBP (ArriVent BioPharma Inc.) posts a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $786.5M). Among the 5-stock peer group, COLL leads on earnings multiple (12.4x) while COLL leads on capital efficiency (85.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for HELP?

For Helus Pharma Inc. (HELP), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #359 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is HELP trading relative to its 50-day, 200-day, and 52-week technical levels?

HELP last traded at $10.71 (-1.83% on volume of 790,395 shares), positioning the stock -10.45% below its 50-day simple moving average ($11.96) and +38.91% above its 200-day simple moving average ($7.71). Across its 52-week range of $3.76 to $15.15, HELP sits at the 61.0% percentile with a 14-day RSI of 44.7 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($9.37 to $12.05).

HELP Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell HELP stock right now?

Helus Pharma Inc. (HELP) currently earns a Roarable Rating of D (Sell — SELL) with 49/100 RQD Confidence. Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.

What is HELP's 12-month price target and RQD AI Jury consensus?

HELP's 12-month base price target is $10.28 (range $8.02 to $15.91), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: HELP RQD Cockpit HELP 12M Forecast HELP Earnings & Move HELP Dividends & DRIP HELP Insiders & 13F HELP Whale Options HELP Profit Sankey HELP News & Why